

- 2 **Přehledové srovnání robotem asistované, laparoskopické a abdominální sakrokolpopexy**
prof. MUDr. Radovan Pilka, Ph.D. | MUDr. Zuzana Maškulíková | MUDr. Daniel Gágyor |
MUDr. Petr Dzvínčuk, Ph.D. Porodnicko-gynekologická klinika, LF UP a FN, Olomouc
- 2 **Modifikovaná Robsonova klasifikace císařských řezů**
MUDr. Vladimír Korečko Gynekologicko-porodnická klinika LF UK a FN, Plzeň
- 2 **Placenta accreta**
MUDr. Michal Kozzerovský | MUDr. Vladimír Korečko Gynekologicko-porodnická klinika FN Plzeň
- 3 **Myomy v graviditě**
MUDr. Lucie Betincová Gynekologicko-porodnická klinika FN Plzeň MUDr. Jaroslava Karbanová | MUDr. Jiří Turek
Gynekologicko-porodnická klinika FN Plzeň, LF v Plzni, UK v Praze
MUDr. Hynek Kudělka, MBA GYNET GROUP, Ostrava (kazuistika 2)
- 3 **Karcinom ovaria 2016**
MUDr. Zdeněk Adamík, Ph.D. | MUDr. Vladimír Kalist
Univerzita T. Bati, gynekologicko-porodnické oddělení, Krajská nemocnice T. Bati, Zlín
- 3 **Poruchy pánevního dna po porodu**
MUDr. Zdeněk Rušavý Gynekologicko-porodnická klinika, LF UK a FN Plzeň, Biomedicínské centrum LF UK v Plzni
- 4 **HIV v gynekologii a urologii**
MUDr. Milan Zlámal Klinika infekčních nemocí 1. LF UK a ÚVN, Vojenská fakultní nemocnice, Praha
- 4 **Aktuální pohled na problematiku kvasinek ve vulvovaginální oblasti**
doc. RNDr. Vladimír Buchta, CSc. Ústav klinické mikrobiologie, LF a FN, Hradec Králové,
Katedra biologických a lékařských věd, Farmaceutická fakulta UK v Hradci Králové
PharmDr. Petr Jílek, CSc. Katedra biologických a lékařských věd, Farmaceutická fakulta UK v Hradci Králové
doc. MUDr. Jiří Špaček, Ph.D., IFEPAG Porodnická a gynekologická klinika, LF a FN, Hradec Králové
- 5 **Pacientka s žilním onemocněním v ordinaci gynekologa**
MUDr. Adam Neumann Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha
- 5 **Roztroušená skleróza a těhotenství: přístup k léčbě a plánování gravidity**
MUDr. Marta Šimůnková Praha
- 5 **Léčba dysmenorey kombinovanou hormonální kontracepcí**
doc. MUDr. Peter Koliba, CSc. Gynekologická ambulance – Gynartis, s. r. o.
- 6 **(Ne)jen vitamin D v graviditě**
MUDr. Jana Čepová, Ph.D., MBA | Ing. Marta Pechová | Ing. Eva Klapková, Ph.D. | Ing. Kateřina Dunovská |
prof. MUDr. Richard Průša, CSc. Ústav lékařské chemie a klinické biochemie, 2. LF a FN v Motole, Praha
- 6 **Farmakologické ukončení těhotenství**
MUDr. Michael Fanta, Ph.D. | MUDr. Karel Crha Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 6 **Gynekologické operace a využití gelu Hyalobarrier**
doc. MUDr. Eduard Kučera, CSc.
Gynekologicko-porodnická klinika 3. LF UK, Praha, Fakultní nemocnice Královské Vinohrady, Praha
- 7 **Transdermální aplikace estrogenní substituční terapie – spojení účinnosti a bezpečnosti**
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 7 **Možnost hormonální léčby akné v ordinaci gynekologa**
MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha, Katedra gynekologie a porodnictví 3. LF UK, Praha,
Katedra gynekologie a porodnictví IPVZ, Praha
- 8 **Prevence karcinomu děložního hrdla na rozcestí: nové přístupy k použití HPV testu**
MUDr. Mgr. Igor Piňos, CSc. Praha

Přehledové srovnání robotem asistované, laparoskopické a abdominální sakrokolpopexie

prof. MUDr. Radovan Pilka, Ph.D. | MUDr. Zuzana Maškulíková | MUDr. Daniel Gágyor |
MUDr. Petr Dzvínčuk, Ph.D. Porodnicko-gynekologická klinika, LF UP a FN, Olomouc

- Abbasy, S. – Kenton, K.: Obliterative procedures for pelvic organ prolapse. *Clin Obstet Gynecol*, 2010, 53, s. 86–98.
- Akl, M. N. – Long, J. B. – Giles, D. L., et al.: Robotic-assisted sacrocolpopexy: technique and learning curve. *Surg Endosc*, 2009, 23, s. 2390–2394.
- Akladios, C. Y. – Dautun, D. – Saussine, C., et al.: Laparoscopic sacrocolpopexy for female genital organ prolapse: establishment of a learning curve. *Eur J Obstet Gynecol Reprod Biol*, 2010, 149, s. 218–221.
- Antosh, D. D. – Grotzke, S. A. – McDonald, M. A., et al.: Short-term outcomes of robotic versus conventional laparoscopic sacral colpopexy. *Female Pelvic Med Reconstr Surg*, 2012, 18, s. 158–161.
- Awad, N. – Mustafa, S. – Amit, A., et al.: Implementation of a new procedure: laparoscopic versus robotic sacrocolpopexy. *Arch Gynecol Obstet*, 2013, 287, s. 1181–1186.
- Beer, M. – Kuhn, A.: Surgical techniques for vault prolapse: a review of the literature. *Eur J Obstet Gynecol Reprod Biol*, 2005, 119, s. 144–155.
- Benson, J. T. – Lucente, V. – McClellan, E.: Vaginal versus abdominal reconstructive surgery for the treatment of pelvic support defects: a prospective randomized study with long-term outcome evaluation. *Am J Obstet Gynecol*, 1996, 175, s. 1418–1421, diskuze s. 1421–1422.
- Bump, R. C. – Mattiasson, A. – Bo, K., et al.: The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. *Am J Obstet Gynecol*, 1996, 175, s. 10–17.
- Clairhout, F. – De Ridder, D. – Roovers, J. P., et al.: Medium-term anatomic and functional results of laparoscopic sacrocolpopexy beyond the learning curve. *Eur Urol*, 2009, 55, s. 1459–1467.
- Collins, S. A. – Tulikangas, P. K. – O'Sullivan, D. M.: Effect of surgical approach on physical activity and pain control after sacral colpopexy. *Am J Obstet Gynecol*, 2012, 206, s. 438 e1–6.
- Cosson, M. – Debodinance, P. – Boukerrou, M., et al.: Mechanical properties of synthetic implants used in the repair of prolapse and urinary incontinence in women: which is the ideal material? *Int Urogynecol J Pelvic Floor Dysfunct*, 2003, 14, s. 169–178, diskuze s. 178.
- Daneshgari, F. – Kefer, J. C. – Moore, C., et al.: Robotic abdominal sacrocolpopexy/sacroteropexy repair of advanced female pelvic organ prolapse (POP): utilizing POP-quantification-based staging and outcomes. *BJU Int*, 2007, 100, s. 875–879.
- DeLancey, J. O.: Anatomic aspects of vaginal eversion after hysterectomy. *Am J Obstet Gynecol*, 1992, 166, s. 1717–1724, diskuze s. 1724–1728.
- DeLancey, J. O. – Morley, G. W.: Total colpocleisis for vaginal eversion. *Am J Obstet Gynecol*, 1997, 176, s. 1228–1232, diskuze s. 1232–1235.
- Di Marco, D. S. – Chow, G. K. – Gettman, M. T., et al.: Robotic-assisted laparoscopic sacrocolpopexy for treatment of vaginal vault prolapse. *Urology*, 2004, 63, s. 373–376.
- Elliott, C. S. – Hsieh, M. H. – Sokol, E. R., et al.: Robot-assisted versus open sacrocolpopexy: a cost-minimization analysis. *J Urol*, 2012, 187, s. 638–643.
- Elliott, D. S. – Frank, I. – Dimarco, D. S., et al.: Gynecologic use of robotically assisted laparoscopy: Sacrocolpopexy for the treatment of high-grade vaginal vault prolapse. *Am J Surg*, 2004, 188, s. 525–565.
- Elliott, D. S. – Krambeck, A. E. – Chow, G. K.: Long-term results of robotically assisted laparoscopic sacrocolpopexy for the treatment of high grade vaginal vault prolapse. *J Urol*, 2006, 176, s. 655–659.
- Fitzgerald, M. P. – Richter, H. E. – Siddique, S., et al.: Colpocleisis: a review. *Int Urogynecol J Pelvic Floor Dysfunct*, 2006, 17, s. 261–271.
- Ganatra, A. M. – Rozet, F. – Sanchez-Salas, R., et al.: The current status of laparoscopic sacrocolpopexy: a review. *Eur Urol*, 2009, 55, s. 1089–1103.
- Geller, E. J. – Parnell, B. A. – Dunivan, G. C.: Robotic vs. abdominal sacrocolpopexy: 44-month pelvic floor outcomes. *Urology*, 2012, 79, s. 532–536.
- Geller, E. J. – Siddiqui, N. Y. – Wu, J. M., et al.: Short-term outcomes of robotic sacrocolpopexy compared with abdominal sacrocolpopexy. *Obstet Gynecol*, 2008, 112, s. 1201–1206.
- Hsiao, K. C. – Latchamsetty, K. – Govier, F. E., et al.: Comparison of laparoscopic and abdominal sacrocolpopexy for the treatment of vaginal vault prolapse. *J Endourol*, 2007, 21, s. 926–930.
- Judd, J. P. – Siddiqui, N. Y. – Barnett, J. C., et al.: Cost-minimization analysis of robotic-assisted, laparoscopic, and abdominal sacrocolpopexy. *J Minim Invasive Gynecol*, 2010, 17, s. 493–499.
- Klauschie, J. L. – Suozzi, B. A. – O'Brien, M. M., et al.: A comparison of laparoscopic and abdominal sacral colpopexy: objective outcome and perioperative differences. *Int Urogynecol J Pelvic Floor Dysfunct*, 2009, 20, s. 273–279.
- Kobashi, K.: Evaluation of Patients with Urinary Incontinence and Pelvic Prolapse. In: Campbell-Walsh, ed. – Sein, A. J. – Kavoussi, L. R. – Novick, A. C., et al.: *Urology*. 10. vydání, Philadelphia, WB Saunders, 2012, s. 1896.
- Maher, C. – Feiner, B. – Baessler, K., et al.: Surgical management of pelvic organ prolapse in women. *Cochrane Database Syst Rev*, 2010, s. CD004014.
- Mahrn, M. A. – Herath, R. P. – Sayed, A. T., et al.: Laparoscopic management of genital prolapse. *Arch Gynecol Obstet*, 2011, 283, s. 1015–1020.
- Nygaard, I. E. – McCreery, R. – Brubaker, L., et al.: Abdominal sacrocolpopexy: a comprehensive review. *Obstet Gynecol*, 2004, 104, s. 805–823.
- Olsen, A. L. – Smith, V. J. – Bergstrom, J. O., et al.: Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. *Obstet Gynecol*, 1997, 89, s. 501–506.
- Paraiso, M. F. – Jelovsek, J. E. – Frick, A., et al.: Laparoscopic compared with robotic sacrocolpopexy for vaginal prolapse: a randomized controlled trial. *Obstet Gynecol*, 2011, 118, s. 1005–1013.
- Paraiso, M. F. – Walters, M. D. – Rackley, R. R., et al.: Laparoscopic and abdominal sacral colpopexies: a comparative cohort study. *Am J Obstet Gynecol*, 2005, 192, s. 1752–1758.
- Seror, J. – Yates, D. R. – Seringe, E., et al.: Prospective comparison of short-term functional outcomes obtained after pure laparoscopic and robot-assisted laparoscopic sacrocolpopexy. *World J Urol*, 2012, 30, s. 393–398.
- Siddiqui, N. Y. – Geller, E. J. – Visco, A. G.: Symptomatic and anatomic 1-year outcomes after robotic and abdominal sacrocolpopexy. *Am J Obstet Gynecol*, 2012, 206, s. 435 e1–5.
- Timmons, M. C. – Addison, W. A. – Addison, S. B., et al.: Abdominal sacral colpopexy in 163 women with posthysterectomy vaginal vault prolapse and enterocele. Evolution of operative techniques. *J Reprod Med*, 1992, 37, s. 323–327.
- von Pechmann, W. S. – Mutone, M. – Fyffe, J., et al.: Total colpocleisis with high levator plication for the treatment of advanced pelvic organ prolapse. *Am J Obstet Gynecol*, 2003, 189, s. 121–126.
- Webb, M. J. – Aronson, M. P. – Ferguson, L. K., et al.: Posthysterectomy vaginal vault prolapse: primary repair in 693 patients. *Obstet Gynecol*, 1998, 92, s. 281–285.

Modifikovaná Robsonova klasifikace císařských řezů

MUDr. Vladimír Korečko Gynekologicko-porodnická klinika LF UK a FN, Plzeň

- Royal College of Obstetricians & Gynaecologists. *Statement on NHS Maternity Statistics, England, 2006–2007*. www.rcog.org.uk, 2008.
- ESRI. *Perinatal Statistics Report 2007*. Health Research Information Division, 2009, www.esri.ie.
- National Center for Health Statistics US. *National Caesarean Rate for 2006*. www.cdc.gov/nchs, 2008.
- WHO. *Rates of Caesarean section; analysis of global, regional and national estimates*. Betran A. Department of Making pregnancy Safer, WHO, Ženeva, Švýcarsko, 2007.
- National Institute for Clinical Excellence: *Clinical Guideline 13. Caesarean Section. Developed by the National Collaborating Centre for Women's and Children's Health*. Dostupné z: www.nice.org.uk/nicemedia/pdf/CG13NICEguideline.pdf, vyhledáno v dubnu 2004.
- Thomas, J., et al.: The national sentinel Caesarean section audit. *BJOG*, 2000, 107, s. 579–580.
- Robson, M. S.: Classification of Caesarean sections. *Fetal and Maternal Medicine Review*. 2001, s. 23–39, DOI: http://dx.doi.org/10.1017/S096539501000122, publikováno online 17. 1. 2001.
- Brennan, D. J. – Robson, M. S. – Murphy, M., et al.: Comparative analysis of international cesarean delivery rates using 10-group classification identifies significant variation in spontaneous labor. *Am J Obstet Gyn*, 2009, s. 308.e1–308.e8.
- Robson, M. S.: Can we reduce the Caesarean section rate? *Best Practice Res Clin Obstet Gynaecol*, 2001, 15, s. 179–194.
- Van Dillen, J. – Lim, F. – Van Rijssel, E.: Introducing Caesarean section audit in a regional teaching hospital in the Netherlands. *Eur J Obstet Gynaecol*, 2008, 139, s. 151–156.
- Robson, M. S. – Scudamore, I. W. – Walsh, S.: Using the medical audit cycle to reduce Caesarean section rates. *Am J Obstet Gynaecol*, 1996, 174, s. 199–205.

Placenta accreta

MUDr. Michal Kozzerovský | MUDr. Vladimír Korečko Gynekologicko-porodnická klinika FN Plzeň

- Cunningham, F. G. – Leveno, K. J. – Bloom, S. L., et al.: *Williams Obstetrics*. 24. vydání, 2014, s. 804–808.
- Calda, P. – Bešťák, M. – Fischerová, D.: *Ultrazvuková diagnostika v těhotenství a gynekologii*, 2010, s. 167.
- Tantbirjon, P. – Crum, C. D. – Parast, M. M.: Pathophysiology of placenta accreta: the role of deciduas and extravillous cytotrophoblast. *Placenta*, 2008, 29, s. 639–645.
- Comstock, C. H. – Love, J. J. – Bronsteen, R. A., et al.: Sonographic detection of placenta accreta in the second and third trimesters of pregnancy. *Am J Obstet Gynecol*, 2004, 190, s. 1135–1140.
- Backmann, C. H. R. B. – Ling, F. W., et al.: *Obstetrics and gynecology*. 6. vydání, 2010, s. 133–137.
- O'Brien, J. M. – Barton, J. R. – Donaldson, E. S.: The management of placenta percreta: conservative and operative strategies. *Am J Obstet Gynecol*, 1996, 175, s. 1632–1638.
- Read, J. A. – Cotton, D. B. – Miller, F. C.: Placenta accreta: changing clinical aspects and outcome. *Obstet Gynecol*, 1980, 56, s. 31–34.

Myomy v graviditě

MUDr. Lucie Betincová Gynekologicko-porodnická klinika FN Plzeň MUDr. Jaroslava Karbanová |
MUDr. Jiří Turek Gynekologicko-porodnická klinika FN Plzeň, LF v Plzni, UK v Praze
MUDr. Hynek Kudělka, MBA GYNET GROUP, Ostrava (kazuistika 2)

- 1 Al-Serehi, A. – Mhoyan, A. – Brown, M., et al.: Placenta accrete: An association with fibroids and Asherman syndrome. *J Ultrasound Med*, 2008, 27, s. 1623–1628.
- 2 Celik, C. – Acar, A. – Cicek, N., et al.: Can myomectomy be performed during pregnancy. *Gynecol Obstet Invest*, 2002, 53, s. 79.
- 3 Coronado, G. D. – Marshall, L. M. – Schwartz, S. M.: Complications in pregnancy, labor and delivery with uterine leiomyomas: a population-based study. *Obstet Gynecol*, 2002, 95, s. 764–769.
- 4 Cunningham, F. G. – Leveno, K. J. – Bloom, S. L., et al.: *Williams Obstetrics*. 23. vydání, New York, McGraw-Hill, Medical Publishing Division, 2010, s. 901–904.
- 5 Donnez, J., et al.: Long-term treatment of uterine fibroids with ulipristal acetate. *Fertil Steril*, 2014, 101, s. 1565–1573.
- 6 Dubuisson, J. B. – Fauconnier, A. – Babaki-Fard, K., et al.: Laparoscopic myomectomy: A current view. *Hum Reprod Update*, 2000, 6, s. 588–594.
- 7 Gago, A. – Diamond, M. P.: Myomas in pregnancy. In: Tulandi, T.: *Uterine fibroids: embolization and other treatments*. Cambridge, Cambridge University Press, 2003, s. 57–64.
- 8 Goldberg, J. – Pereira, L.: Pregnancy outcomes following treatment for fibroids: Uterine fibroid embolization versus laparoscopic myomectomy. *Curr Opin Obstet Gynecol*, 2006, 18, s. 402–406.
- 9 James, D. – Steer, P. J. – Werner, C. P., et al.: *High Risk Pregnancy, Management Options*. 4. vydání, St. Louis, Elsevier Saunders, 2011, s. 1029–1030.
- 10 Joó, J. G. – Inovay, J. – Silhavy, M., et al.: Successful enucleation of a necrotizing fibroid causing oligohydramnios and fetal postural deformity in the 25th week of gestation. *J Reprod Med*, 2001, 46, s. 923.
- 11 Kolařík, D. – Halaška, M. – Feyeireisl, J., et al.: *Repetitorium gynekologie*. Praha, Maxdorf, 2008, s. 753–758.
- 12 Laughlin, S. K. – Baird, D. D. – Savitz, D. A., et al.: Prevalence of uterine leiomyomas in first trimester of pregnancy. *Obstet Gynecol*, 2009, 118, s. 630–635.
- 13 Mára, M. – Holub, Z., et al.: *Děložní myomy*. Praha, Grada Publishing, 2009, s. 55–64.
- 14 Mollica, G. – Pittini, L. – Minganti, E., et al.: Elective uterine myomectomy in pregnant women. *Clin Exp Obstet Gynecol*, 1996, 23, s. 168–170.
- 15 Qidwai, G. I. – Caughey, A. B. – Jacoby, A. F.: Obstetric outcomes in women with sonographically identified uterine leiomyomata. *Obstet Gynecol*, 2006, 107, s. 377–378.
- 16 Rice, J. P. – Kay, H. H. – Mahony, B. S.: The clinical significance of uterine leiomyoma in pregnancy. *Am J Obstet Gynecol*, 1989, 160, s. 1212–1216.
- 17 Venkat, G. – Amiri, N. – Al-Nasser, R., et al.: The effect of submucosal, intramural and subserosal uterine fibroids on the pregnancy outcome in oocyte recipients. *Fertil Steril*, 2005, 84, s. 258.

Karcinom ovaria 2016

MUDr. Zdeněk Adamík, Ph.D. | MUDr. Vladimír Kalist

Univerzita T. Bati, gynekologicko-porodnické oddělení, Krajská nemocnice T. Bati, Zlín

- 1 Cibula, D. – Petruželka, L.: *Onkogynekologie*. Grada publishing, 2009, s. 49–59, s. 508–531.
- 2 Calda, P. – Břešťák, M. – Fisherová, D.: *Ultrazvuková diagnostika v těhotenství a gynekologii*. Aprofema, 2010, 2, s. 459–467.
- 3 Kurman, R. J. – le-Ming Shih, M. D.: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. Shifting the paradigm. *Human Pathology*, 2012, 42, s. 918–931.
- 4 Fathalla, M. F.: Incessant ovulation—a factor in ovarian neoplasia? *Lancet*, 1971, 298, s. 163.
- 5 Cramer, D. W. – Welch, W. R.: Determinants of ovarian cancer risk. *Natl Cancer Inst*, 1983, 71, s. 717–721.
- 6 Vanderhyden, B. C. – Shaw, T. J. – Ethier, J. F.: Animal model of ovarian cancer. *Reprod Biol Endocrinol*, 2003, 1, s. 1–11.
- 7 Zikán, M. – Cibula, D. – Fischerová, D., et al.: Guideline gynekologických zhoubných nádorů: standard komplexní léčby ovariálních epitelálních zhoubných nádorů. Dostupné z: www.onkogynekologie.com.
- 8 Shih, K. K. – Chi, D. S.: Maximal cytoreductive effort in epithelial ovarian cancer surgery. *J Gynecol Oncol*, 2010, 21, s. 75–80.
- 9 Kehoe, S. M. – Eisenhauer, E. L. – Chi, D. S.: Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy. *Gynecol Oncol*, 2008, 111, s. 51–55.
- 10 Klener, P., et al.: *Klinická onkogynekologie*. Galén, 2002, s. 485–487.
- 11 Chi, D. S. – Eisenhauer, E. L. – Lang, J., et al.: What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? *Gynecol Oncol*, 2006, 103, s. 559–564, Epub 22. 5. 2006.
- 12 du Bois, A. – Reussi, A. – Pujade-Lauraine, E., et al.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). *Cancer*, 2009, 115, s. 1234–1244.
- 13 Vergote, I. – Tropé, C. G. – Amin, F., et al.: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med*, 2010, 363, s. 943–953.
- 14 Kehoe, S. – Hook, J. – Nankivell, M., et al.: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. *Lancet*, 2015, 386, s. 249–257.
- 15 Ferrandina, G. – Sallustio, G. – Fagotti, A., et al.: Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. *Br J Cancer*, 2009, 101, s. 1066–1073.
- 16 Denzer, U. – Hoffmann, S., et al.: Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomography. *Surg Endosc*, 2004, 18, s. 1067–1070.
- 17 Fagotti, A. – Fanfani, F. – Ludovisi, M., et al.: Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. *Gyn Oncol*, 2005, 96, s. 729–735.
- 18 Fagotti, A. – Ferrandina, G. – Fanfani, F., et al.: A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. *An Surg Oncol*, 2006, 13, s. 1156–1161.
- 19 Hauspy, J. – Pouseele, B. – Van Wiemeersch, J., et al.: The role of laparoscopy in the evaluation and treatment of epithelial ovarian cancer. *Belg J Med Oncol*, 2012, 6, s. 157–163.
- 20 Van Dam, P. A. – DeCloedt, J. – Tjalma, W. A., et al.: Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced? *Am J Obst Gyn*, 1999, 181, s. 536–541.
- 21 Adamík, Z. – Krupková, S.: Karcinom ovaria 2014. *ACTA MEDICINAE*, 2014, 4, s. 48–50.
- 22 Gelmon, K. A. – Tischkowitz, M. – Mackay, H., et al.: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. *Lancet Oncol*, 2011, 12, s. 852–861.
- 23 Ledermann, J., et al.: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. *The Lancet Oncology*, 2014, 15, s. 852–861, DOI: 10.1016/S1473-2045(14)70228-1.

Poruchy pánevního dna po porodu

MUDr. Zdeněk Rušavý

Gynekologicko-porodnická klinika, LF UK a FN Plzeň, Biomedicínské centrum LF UK v Plzni

- 1 Macarthur, A. J. – Macarthur, C.: Incidence, severity, and determinants of perineal pain after vaginal delivery: a prospective cohort study. *American Journal of Obstetrics and Gynecology*, 2004, 191, s. 1199–1204.
- 2 Karbanová, J. – Rusavý, Z. – Betincová, L. – Jansova, M. – Necessalova, P. – Kalis, V.: Clinical evaluation of early postpartum pain and healing outcomes after mediolateral versus lateral episiotomy. *International Journal of Gynecology & Obstetrics*, 2014, 127, s. 152–156.
- 3 Fodstad, K. – Staff, A. C. – Laine, K.: Effect of different episiotomy techniques on perineal pain and sexual activity 3 months after delivery. *International Urogynecology Journal*, 2014, 25, s. 1629–1637.
- 4 Carroli, G. – Mignini, L.: Episiotomy for vaginal birth. The Cochrane database of systematic reviews, 2009, CD000081. PubMed PMID: 19160176, Epub 23. 1. 2009.
- 5 Necessalova, P. – Karbanova, J. – Rusavy, Z. – Pastor, Z. – Jansova, M. – Kalis, V.: Mediolateral versus lateral episiotomy and their effect on postpartum coital activity and dyspareunia rate 3 and 6 months postpartum. *Sexual & Reproductive Healthcare*, 2016, online před tiskem.
- 6 LaCross, A. – Groff, M. – Smaldone, A.: Obstetric anal sphincter injury and anal incontinence following vaginal birth: A systematic review and metaanalysis. *Journal of Midwifery & Women's Health*, 2015, 60, s. 37–47.
- 7 Barrett, G. – Pendry, E. – Peacock, J., et al.: Women's sexual health after childbirth. *BJOG: An International Journal of Obstetrics & Gynaecology*, 2000, 107, s. 186–195.
- 8 Gyhagen, M. – Bullarbo, M. – Nielsen, T., et al.: The prevalence of urinary incontinence 20 years after childbirth: a national cohort study in singleton primiparous after vaginal or caesarean delivery. *BJOG: An International Journal of Obstetrics & Gynaecology*, 2013, 120, s. 144–151.
- 9 Smith, T. M. – Luo, J. – Hsu, Y., et al.: A novel technique to measure in vivo uterine suspensory ligament stiffness. *American Journal of Obstetrics and Gynecology*, 2013, 209, s. 484, e1–e7.
- 10 Yousof, A. – Chen, L. – Larson, K., et al.: The length of anterior vaginal wall exposed to external pressure on maximal straining MRI: relationship to urogenital hiatus diameter, and apical and bladder location.

- International Urogynecology Journal*, 2014, s. 1–8.
- 11 Chen, L. – Ashton-Miller, J. A. – Hsu, Y., et al.: Interaction among apical support, levator ani impairment, and anterior vaginal wall prolapse. *Obstetrics and Gynecology*, 2006, 108, s. 324–332.
 - 12 Dietz, H. – Shek, C. – Clarke, B.: Biometry of the pubovisceral muscle and levator hiatus by three-dimensional pelvic floor ultrasound. *Ultrasound in Obstetrics & Gynecology*, 2005, 25, s. 580–585.
 - 13 Lien, K. C. – Mooney, B. – DeLancey, J. O., et al.: Levator ani muscle stretch induced by simulated vaginal birth. *Obstetrics and Gynecology*, 2004, 103, s. 31.
 - 14 Brooks, S. V. – Zerba, E. – Faulkner, J. A.: Injury to muscle fibres after single stretches of passive and maximally stimulated muscles in mice. *The Journal of Physiology*, 1995, 488, s. 459–469.
 - 15 Dietz, H. P.: Pelvic floor trauma in childbirth. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 2013, 53, s. 220–230.
 - 16 Dietz, H. P. – Shek, C. – De Leon, J. – Steensma, A.: Ballooning of the levator hiatus. *Ultrasound in Obstetrics & Gynecology*, 2008, 31, s. 676–680.
 - 17 Gainey, H. L.: Post-partum observation of pelvic tissue damage. *American Journal of Obstetrics and Gynecology*, 1943, 45, s. 457–466.
 - 18 Dietz, H. P. – Lanzarone, V.: Levator trauma after vaginal delivery. *Obstetrics & Gynecology*, 2005, 106, s. 707–712.
 - 19 DeLancey, J. O. – Kearney, R. – Chou, Q. – Speights, S. – Binno, S.: The appearance of levator ani muscle abnormalities in magnetic resonance images after vaginal delivery. *Obstetrics & Gynecology*, 2003, 101, s. 46–53.
 - 20 Allen, R. – Hosker, G. – Smith, A. – Warrell, D.: Pelvic floor damage and childbirth: a neurophysiological study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 1990, 97, s. 770–779.
 - 21 Lien, K. C. – Morgan, D. M. – Delancey, J. O. – Ashton-Miller, J. A.: Pudendal nerve stretch during vaginal birth: a 3D computer simulation. *American Journal of Obstetrics and Gynecology*, 2005, 192, s. 1669–1676.
 - 22 Brown, R. – Pedowitz, R. – Rydevik, B., et al.: Effects of acute graded strain on efferent conduction properties in the rabbit tibial nerve. *Clinical Orthopaedics and Related Research*, 1993, 296, s. 288.
 - 23 Jou, I. – Lai, K. A. – Shen, C. L. – Yamano, Y.: Changes in conduction, blood flow, histology, and neurological status following acute nerve—stretch injury induced by femoral lengthening. *Journal of Orthopaedic Research*, 2000, 18, s. 149–155.
 - 24 Snooks, S. J.: Effects of childbirth. *Colorectal Physiology Fecal Incontinence*, 1994, s. 41.
 - 25 Liang, C. C. – Wu, M. P. – Lin, S. J., et al.: Clinical impact of and contributing factors to urinary incontinence in women 5 years after first delivery. *International Urogynecology Journal*, 2013, 24, s. 99–104.
 - 26 Lal, M. – Mann, C. H. – Callender, R. – Radley, S.: Does cesarean delivery prevent anal incontinence? *Obstetrics & Gynecology*, 2003, 101, s. 305–312.
 - 27 Bazi, T. – Takahashi, S. – Ismail, S., et al.: Prevention of pelvic floor disorders: international urogynecological association research and development committee opinion. *International Urogynecology Journal*, 2016, s. 1–11.
 - 28 MacArthur, C. – Bick, D. – Keighley, M.: Faecal incontinence after childbirth. *British Journal of Obstetrics and Gynaecology*, 1997, 104, s. 46.
 - 29 Chin, H. Y. – Chen, M. C. – Liu, Y. H., et al.: Postpartum urinary incontinence: a comparison of vaginal delivery, elective, and emergent cesarean section. *International Urogynecology Journal*, 2006, 17, s. 631–635.
 - 30 Groutz, A. – Rimon, E. – Peled, S., et al.: Cesarean section: does it really prevent the development of postpartum stress urinary incontinence? A prospective study of 363 women one year after their first delivery. *Neurology and Urodynamics*, 2004, 23, s. 2–6.
 - 31 Albrich, S. – Laterza, R. – Skala, C., et al.: Impact of mode of delivery on levator morphology: a prospective observational study with three-dimensional ultrasound early in the postpartum period. *BJOG: An International Journal of Obstetrics & Gynaecology*, 2012, 119, s. 51–61.
 - 32 Rortveit, G. – Daltveit, A. K. – Hannestad, Y. S., et al.: Urinary incontinence after vaginal delivery or cesarean section. *New England Journal of Medicine*, 2003, 348, s. 900–907.
 - 33 MacArthur, C. – Glazener, C. – Lancashire, R., et al.: Exclusive caesarean section delivery and subsequent urinary and faecal incontinence: a 12-year longitudinal study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 2011, 118, s. 1001–1007.
 - 34 Nygaard, I. E. – Rao, S. S. – Dawson, J. D.: Anal incontinence after anal sphincter disruption: a 30-year retrospective cohort study. *Obstetrics & Gynecology*, 1997, 89, s. 896–901.
 - 35 Fritel, X. – Ringa, V. – Varnoux, N., et al.: Mode of delivery and fecal incontinence at midlife: a study of 2,640 women in the Gazel cohort. *Obstetrics & Gynecology*, 2007, 110, s. 31–38.
 - 36 Mous, M. – Muller, S. – De Leeuw, J.: Long-term effects of anal sphincter rupture during vaginal delivery: faecal incontinence and sexual complaints. *BJOG: An International Journal of Obstetrics & Gynaecology*, 2008, 115, s. 234–238.
 - 37 Halle, T. K. – Salvesen, K. Å. – Volloyhaug, I.: Obstetric anal sphincter injury and incontinence 15–23 years after vaginal delivery. *Acta Obstetrica et Gynecologica Scandinavica*, 2016, online před tiskem.
 - 38 Gyhagen, M. – Bullarbo, M. – Nielsen, T. – Milsom, I.: Prevalence and risk factors for pelvic organ prolapse 20 years after childbirth: a national cohort study in singleton primiparae after vaginal or caesarean delivery. *BJOG: An International Journal of Obstetrics & Gynaecology*, 2013, 120, s. 152–160.
 - 39 Kearney, R. – Miller, J. M. – Ashton-Miller, J. A. – DeLancey, J. O.: Obstetrical factors associated with levator ani muscle injury after vaginal birth. *Obstetrics and Gynecology*, 2006, 107, s. 144.
 - 40 Krofta, L. – Otčenášek, M. – Kašíková, E. – Feyereisl, J.: Pubococcygeus-puborectalis trauma after forceps delivery: evaluation of the levator ani muscle with 3D/4D ultrasound. *International Urogynecology Journal*, 2009, 20, s. 1175–1181.
 - 41 Shek, K. L. – Dietz, H. P.: The effect of childbirth on hiatal dimensions. *Obstetrics & Gynecology*, 2009, 113, s. 1272–1278.

HIV v gynekologii a urologii

MUDr. Milan Zlámal Klinika infekčních nemocí 1. LF UK a ÚVN, Vojenská fakultní nemocnice, Praha

- 1 Hoffmann, Ch. – Rockstroh, J. K.: *HIV book 2015/2016*, dostupné z: <https://hivbook.com/>, vyhledáno 19. 5. 2016.
- 2 Mandell, Douglas, and Bennett's *Principles and Practices of Infectious Diseases*, 8. verze, 2015, s. 2054–2056.
- 3 Zprávy SZÚ NRL pro HIV, dostupné z: <http://www.szu.cz/tema/prevence/rocnizpravy-o-vyskytu-a-sireni-hiv-aids-v-cr>, vyhledáno 19. 5. 2016.
- 4 Zprávy SZÚ NRL pro HIV, dostupné z: http://www.szu.cz/uploads/documents/CeM/HIV_AIDS/rocnizpravy/2016/HIV_AIDS_03_2016.pdf, vyhledáno 19. 5. 2016.
- 5 Informace dostupné z: <http://www.unaids.org/>, vyhledáno 19. 5. 2016.
- 6 Informace dostupné z: <http://www.eacsociety.org/>
- 7 Informace dostupné na: <http://www.infekce.cz/DoporART16.htm>, vyhledáno 19. 5. 2016.
- 8 Informace dostupné na: <http://www.cdc.gov/hiv/basics/prep.html>, vyhledáno 19. 5. 2016.

Aktuální pohled na problematiku kvasinek ve vulvovaginální oblasti

doc. RNDr. Vladimír Buchta, CSc. Ústav klinické mikrobiologie, LF a FN, Hradec Králové,
Katedra biologických a lékařských věd, Farmaceutická fakulta UK v Hradci Králové
PharmDr. Petr Jílek, CSc.

Katedra biologických a lékařských věd, Farmaceutická fakulta UK v Hradci Králové

doc. MUDr. Jiří Špaček, Ph.D., IFEPAG Porodnická a gynekologická klinika, LF a FN, Hradec Králové

- 1 Allen-Davis, J. T. – Beck, A. – Parker, R., et al.: Assessment of vulvovaginal complaints: accuracy of telephone triage and in-office diagnosis. *Obstet Gynecol*, 2002, 99, s. 18–22.
- 2 Anderson, M. R. – Klink, K. – Cochrans, A.: Evaluation of vaginal complaints. *JAMA*, 2004, 291, s. 136–179.
- 3 Buchta, V. – Špaček, J.: Mikrobiologické nálezy u pacientek s rekurentní vulvovaginální kandidózou ve Fakultní nemocnici Hradec Králové v letech 1995–2004. *Českoslov Gynecol*, 2004, 69, s. 7–14.
- 4 Buchta, V. – Špaček, J.: Úskalí současné laboratorní diagnostiky a terapie vulvovaginální kandidózy. *Klin Mikrobiol Infekc Lek*, 2011, 17, s. 158–163.
- 5 Buchta, V. – Špaček, J. – Jílek, P.: Mykotické infekce ženského genitálu I. Epidemiologie a mikrobiologie. *Gynekolog*, 1997, 2, s. 67–70.
- 6 Buchta, V. – Špaček, J. – Jílek, P.: Mykotické infekce ženského genitálu II. Diagnostika. *Gynekolog*, 1997, 4, s. 173–175.
- 7 Buchta, V. – Špaček, J. – Jílek, P.: Mykotické infekce ženského genitálu III. Terapie. *Gynekolog*, 1998, 7, s. 73–82.
- 8 Bulik, C. C. – Sobel, J. D. – Nailor, M. D.: Susceptibility profile of vaginal isolates of *Candida albicans* prior to and following fluconazole introduction—impact of two decades. *Mycoses*, 2011, 54, s. 34–38.
- 9 Calderone, R. A. – Fonzi, W. A.: Virulence factors of *Candida albicans*. *Trends Microbiol*, 2001, 9, s. 327–335.
- 10 Dan, M. – Poch, F. – Levin, D.: High rate of vaginal infections caused by non-*C. albicans* *Candida* species among asymptomatic women. *Med Mycol*, 2002, 40, s. 383–386.
- 11 Drell, T. – Lillaar, T. – Tummeleht, L., et al.: Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women. *PLoS ONE*, 2013, 8, e54379, doi:10.1371/journal.pone.0054379.
- 12 Eschenbach, D. A.: Vaginal infection. *Clin Obstet Gynecol*, 1983, 26, s. 186–202.
- 13 Eschenbach, D. A.: Chronic vulvovaginal candidiasis. *N Engl J Med*, 2004, 351, s. 851–852.
- 14 Geiger, A. M. – Foxman, B. – Gillespie, B. W.: The epidemiology of vulvovaginal candidiasis among university students. *Am J Public Health*, 1995, 85, s. 1146–1148.
- 15 Guzel, A. B. – Ilkit, M. – Burgut, R., et al.: An evaluation of risk factors in pregnant women with *Candida* vaginitis and the diagnostic value of simultaneous vaginal and rectal sampling. *Mycopathologia*, 2011, 172, s. 25–36.
- 16 Hillier, S. L.: Self-diagnosis and over-the-counter treatment. *Clinician*, 1994, 12, s. 12–15.
- 17 Houang, E. T. – Chappatte, O. – Byrne, D., et al.: Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. *Antimicrob Agents Chemother*, 1990, 34, s. 909–910.
- 18 Chen, C. K. – Chang, D. Y. – Chang, S. C., et al.: Cryptococcal infection of the vagina. *Obstet Gynecol*, 1993, 81, s. 867–869.
- 19 Jones, G. R. – Warnock, D. W.: Observations on the use of the double diffusion test in the diagnosis of vaginal candidiasis. *J Clin Pathol*, 1977, 30, s. 262–265.

- 20 Ledger, W. J. – Polaneczky, M. M. – Yih, M. C., et al.: Difficulties in the diagnosis of Candida vaginitis. *Infect Dis Clin Pract*, 2000, 9, s. 66–69.
- 21 Lynch, M. E. – Sobel, J. D.: Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. *J Med Vet Mycol*, 1994, 32, s. 267–274.
- 22 MacCallum, D. M. – Castillo, L. – Nather, K., et al.: Property differences among the four major Candida albicans strain clades. *Eukaryot Cell*, 2009, 8, s. 373–387.
- 23 Makela, P. – Leaman, D. – Sobel, J. D.: Vulvovaginal trichomonososis. *Infect Dis Obstet Gynecol*, 2003, 11, s. 131–133.
- 24 Mårdh, P. A. – Novikova, N. – Witkin, S. S., et al.: Detection of Candida by polymerase chain reaction vs microscopy and culture in women diagnosed as recurrent vulvovaginal cases. *Int J STD AIDS*, 2003, 14, s. 753–756.
- 25 McCullough, M. J. – Clemons, K. V. – Farina, C., et al.: Epidemiological investigation of vaginal Saccharomyces cerevisiae isolates by a genotypic method. *J Clin Microb*, 1998, 36, s. 557–562.
- 26 Mendling, W., et al.: Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). *Mycoses*, 2015, 58, s. 1–15.
- 27 Mercure, S. – Poirier, S. – Lemay, G., et al.: Application of biotyping and DNA typing of Candida albicans to the epidemiology of recurrent vulvovaginal candidiasis. *J Infect Dis*, 1993, 168, s. 502–507.
- 28 Nyirjesy, P. – Seeney, S. M. – Grody, M. H. T., et al.: Chronic fungal vaginitis: the value of cultures. *Am J Obstet Gynecol*, 1995, 173, s. 820–823.
- 29 Nyirjesy, P. – Vazquez, J. A. – Ufberg, D. D., et al.: Saccharomyces cerevisiae vaginitis: transmission from yeast used in baking. *Obstet Gynecol*, 1995, 86, s. 326–329.
- 30 Odds, F. C.: Epidemiological shifts in opportunistic and nosocomial Candida infections: mycological aspects. *Int J Antimicrob Agents*, 1996, 6, s. 141–144.
- 31 Palmeira-de-Oliveira, R. – Palmeira-de-Oliveira, A. – Martinez-de-Oliveira, J.: New strategies for local treatment of vaginal infections. *Adv Drug Deliv Rev*, 2015, 92, s. 105–122.
- 32 Reed, B.: Risk factors for candida vulvovaginitis. *Obstet Gynecol Surv*, 1992, 47, s. 551–560.
- 33 Regúlez, P. – García Fernández, J. F. – Moragues, M. D., et al.: Detection of anti-Candida albicans IgE antibodies in vaginal washes from patients with acute vulvovaginal candidiasis. *Gynecol Obstet Invest*, 1994, 37, s. 110–114.
- 34 Sobel, J. D.: Vulvovaginal candidiasis. *Lancet*, 2007, 369, s. 1961–1971.
- 35 Sobel, J. D. – Faro, S. – Force, R. W., et al.: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. *Am J Obstet Gynecol*, 1998, 178, s. 203–211.
- 36 Sobel, J. D. – Chaim, W.: Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. *J Clin Microbiol*, 1996, 34, s. 2497–2499.
- 37 Sobel, J. D. – Schmitt, C. – Meriwether, C.: A new slide latex agglutination test for the diagnosis of acute Candida vaginitis. *Am J Clin Pathol*, 1990, 94, s. 323–325.
- 38 Sobel, J. D. – Vaquez, J. – Lynch, M., et al.: Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy. *Clin Infect Dis*, 1993, 16, s. 93–99.
- 39 Sojakova, M. – Liptajova, D. – Borovsky, M., et al.: Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia. *Mycopathologia*, 2004, 157, s. 163–169.
- 40 Spinillo, A. – Capuzzo, E. – Egbe, T. O., et al.: Torulopsis glabrata vaginitis. *Obstet Gynecol*, 1995, 85, s. 993–998.
- 41 Spinillo, A. – Capuzzo, F. – Nicola, S., et al.: The impact of oral contraception on vulvovaginal candidiasis. *Contraception*, 1995, 51, s. 293–297.
- 42 Spinillo, A. – Zera, F. – Gardella, B., et al.: The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions. *Am J Obstet Gynecol*, 2005, 192, s. 774–779.
- 43 Špaček, J. – Buchta, V. – Jílek, P., et al.: Vulvovaginální dyskomfort a poruchy poševního prostředí. Grada, Praha, 2013, s. 359.
- 44 Špaček, J. – Buchta, V. – Jílek, P. – Forst, M.: Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. *Eur J Obstet Gynecol Rep Biol*, 2007, 131, s. 198–202.
- 45 Špaček, J. – Buchta, V. – Jílek, P. – Halada, P., et al.: Současné trendy v léčbě vulvovaginálního diskomfortu. *Med Pro Praxi*, 2011, 8, s. 77–82.
- 46 Špaček, J. – Buchta, V. – Kestránek, J.: Vulvovaginální dyskomfort mykotického původu – současný stav a léčebné možnosti. *Interní Med*, 2012, 14, s. 119–121.
- 46 Špaček, J. – Jílek, P. – Buchta, V., et al.: The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls. *Mycoses*, 2005, 48, s. 391–395.
- 47 Warnock, D. W. – Hilton, A. L.: Value of the indirect immunofluorescence test in the diagnosis of vaginal candidiasis. *Br J Vener Dis*, 1976, 52, s. 187–189.
- 48 Weissenbacher, T. – Witkin, S. S. – Ledger, W. J., et al.: Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of Candida species by culture and polymerase chain reaction. *Arch Gynecol Obstet*, 2009, 279, s. 125–129.
- 49 Witkin, S. S. – Jeremias, J. – Ledger, W. J.: Vaginal eosinophils and IgE antibodies to Candida albicans in women with recurrent vaginitis. *J Med Vet Mycol*, 1989, 27, s. 57–58.
- 50 Xu, J. – Sobel, J. D.: Antibiotic-associated vulvovaginal candidiasis. *Curr Infect Dis Rep*, 2003, 5, s. 481–487.

Pacientka s žilním onemocněním v ordinaci gynekologa

MUDr. Adam Neumann Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha

- 1 Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. *Chronická žilní onemocnění. Léčebné standardy*. Seznam doporučených postupů pro praktické lékaře, 2011, dostupné z: <http://www.cls.cz/seznam-doporučených-postupů>.
- 2 Pospíšilová, A. – Švestková, S.: Chronické žilní onemocnění je závažnější, než si přepouštíme. *Medicina pro praxi*, 2010, 1, s. 50–54.
- 3 Pospíšilová, A.: Symptomy u chronického žilního onemocnění. *Bulletin sdružení praktických lékařů ČR*, 2013, 3, s. 54–58.
- 4 Kaletová, D.: Farmakologická léčba chronické žilní nemoci. *Angiologie*, 2009, 3, s. 96–104.
- 5 Boisseau, M. R.: Pharmacological targets of drugs employed in chronic venous and lymphatic insufficiency. *Int Angiol*, 2002, 21, s. 33–39.
- 6 Reich, S. – Altmayer, P. – Stucker, M.: Systemische medikamentöse Therapie von chronischen Venenerkrankungen. *Hautarzt*, 2006, 57, s. 9–18.
- 7 Nicolaidis, A. N. – Perin, M.: Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. *Int Angiology*, 2014, 33, s. 126–139.
- 8 Tsoukanov, Y. T. – Tsoukanov, A. Y. – Nikolaychuk, A.: Great saphenous vein transitory reflux in patients with symptoms related to chronic venous disorders but without visible signs (COs), and its correlation with MPFF treatment. *Phlebology*, 2015, 22, s. 18–24.

Roztroušená skleróza a těhotenství: přístup k léčbě a plánování gravidity

MUDr. Marta Šimůnková Praha

- 1 Hanulíková, P., et al.: Těhotenství a roztroušená skleróza – analýza výsledků z let 2003–2011. *Čes Gynek*, 2013, 78, s. 142–148.
- 2 Hellwig, K.: *Multiple sclerosis in pregnancy: Treatment planning and approach*. *Multiple Sclerosis Management*, 2016, *A Lifetime of Fragment*, s. 198–210, doi: 10.1177/1756285616631897, Epub 2. 3. 2016.
- 3 Coyle, P. K.: Management of women with multiple sclerosis through pregnancy and after childbirth. *Ther Adv Neurol Disord*, 2016, 9,

Léčba dysmenorey kombinovanou hormonální kontracepcí

doc. MUDr. Peter Koliba, CSc. Gynekologická ambulance – Gynartis, s. r. o.

- 1 Agarwal, A. K. – Agarwal, A.: A study of dysmenorrhea during menstruation in adolescent girls. *Indian J Community Med*, 2010, 35, s. 159–164.
- 2 Balbi, C., et al.: Influence of menstrual factors and dietary habits on menstrual pain in adolescence age. *Eur J Obstet Gynecol Reprod Biol*, 2000, 91, s. 143–148.
- 3 Burnett, M. A., et al.: Prevalence of primary dysmenorrhea in Canada. *J Obstet Gynaecol Can*, 2005, 27, s. 765–770.
- 4 Callejo, J. – Diaz, J. – Ruiz, A. – Garcia, R. M.: Effect of a low-dose oral contraceptive containing 20 gethinylestradiol and 150 g desogestrel on dysmenorrhea. *Contraception*, 2003, 68, s. 183–188.
- 5 Davis, A. R. – Westhoff, C. L.: Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. *J Pediatr Adolesc Gynecol*, 2001, 14, s. 3–8.
- 6 Dawood, M. Y.: Primary dysmenorrhea. Advances in pathogenesis and management. *Obstet Gynecol*, 2006, 108, s. 428–441.
- 7 Epstein, A. G.: *Adolescent dysmenorrhea conclusion*, Arm Med Media, 2011, dostupné z: <http://www.healtham/gyneco/more/adolescent-dysmenorrhea>, vyhledáno 2. 5. 2016.
- 8 George, A. – Bhaduri, A.: Dysmenorrhea among adolescent girls—symptoms experienced during menstruation. *Health Promotion Educ*, 2002, 17, s. 4.
- 9 Geržová, H.: Současný pohled na hormonální antikoncepci u adolescentek. *Gynekolog*, 2005, 14, s. 156–160.
- 10 Hendrix, S. L. – Alexander, N. J.: Primary dysmenorrhea treatment with a desogestrel—containing low-dose oral contraceptive. *Contraception*, 2002, 66, s. 393–399.
- 11 Koliba, P.: Menstruační bolesti. *Praktické lékařství*, 2010, 6, s. 232–234.
- 12 Kraus, V., et al.: *Dysmenorea a možnosti jejího managementu*, 2012, dostupné z: <http://www.upjs.sk/public/media/7402/2012-10-04-LE-KARSKE-LISTY-Dysmenorea.pdf>, vyhledáno 2. 5. 2016.
- 13 Lincova, D. – Farghali, H., et al.: Základní a aplikovaná farmakologie, GALEN, 2007, dostupné z: <http://www.wikiskripta.eu/index.php/Prostaglandiny>, vyhledáno 2. 5. 2016.
- 14 Lundstrom, V.: Uterine activity during the normal cycle and dysmenorrhea; in Dawood MY (ed): *Dysmenorrhea*. Baltimore, Williams & Wilkins, 1981, s. 53–74.
- 15 Pitts, M. K., et al.: Prevalence and correlates of three types of pelvic pain in a nationally representative sample of Australian women. *Med*

- J Aust*, 2008, 189, s. 138–143.
- 16 Proctor, M. L., et al.: Dysmenorrhea. *Clin Evid*, 2002, 7, s. 1639, dostupné z: <http://www.healtham/gyneco/more/dysmenorrhea>, vyhledáno 2. 5. 2016.
 - 17 Proctor, M. L. – Smith, C. A. – Farquhar, C. M. – Stones, R. W.: Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. *Cochrane Database Syst Rev*, 2002, CD002123.
 - 18 Smith, R. P.: Optimální léčba dysmenorey. *Gynekologie po promoci*, 2007, 2, s. 30.
 - 19 Sanfilippo, J. S.: Oh, the dilemma of dysmenorrhea—What's new? *J Pediatr Adolesc Gynecol*, 2001, 14, s. 1–2.
 - 20 Schroeder, B. – Sanfilippo, J. S.: Dysmenorrhea and pelvic pain in adolescents. *Pediatr Clin North Am*, 1999, 46, s. 555–571.
 - 21 Sultan, C. – Gaspari, L. – Paris, F.: Adolescent dysmenorrhea. *Endocr Dev*, 2012, 22, s. 171–180.
 - 22 Sultan, C.: Adolescent dysmenoreia, pediatric and adolescent gynecology. Evidence based clinical practice. *Endocr Dev Basel*, Karger, 2004, s. 140–147.
 - 23 Sultan, N. – Sultan, C. – Rey, R. – Jean, R.: Variations of plasma 13,14-dihydro-15-ceto-prostaglandins F2a—in adolescent dysmenorrhea. *Pediatr Res*, 1984, 18, s. 104.
 - 24 Tonini, G.: Dysmenorrhea, endometriosis and premenstrual syndrome. *Minerva Pediatr*, 2002, 54, s. 525–538.
 - 25 Unsal, A., et al.: Prevalence of dysmenorrhea and its effect on quality of life among a group of female university students. *Ups J Med Sci*, 2010, 115, s. 138–145.

(Ne)jen vitamin D v graviditě

MUDr. Jana Čepová, Ph.D., MBA | Ing. Marta Pechová | Ing. Eva Klapková, Ph.D. |
Ing. Kateřina Dunovská | prof. MUDr. Richard Průša, CSc.

Ústav lékařské chemie a klinické biochemie, 2. LF a FN v Motole, Praha

- 1 Bálková, O.: Nedostatek vitamínu D v těhotenství. *Labor Aktuell*, 2015, 3, s. 2015.
- 2 Viljakainen, H. T. – Korhonen, T. – Hytinen, T., et al.: Maternal vitamin D status affects bone growth in early childhood—a prospective cohort study. *Osteoporosis Int*, 2011, 22, s. 883–891.
- 3 Aghajafari, F. – Nagulesapillai, T. – Ronksley, P. E., et al.: Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. *MBJ*, 2013, 346, f1169.
- 4 Salle, B. L. – Delvin, E. – Lapillonne, A., et al.: Perinatal metabolism of vitamin D. *Am J Clin Nutr*, 2000, 71, s. S1317–S1324.
- 5 Grant, C. C. – Stewart, A. W. – Scragg, R., et al.: Vitamin D during pregnancy and infancy and infant serum 25-hydroxyvitamin D concentration. *Pediatrics*, 2013, 133, s. e143–e153.
- 6 Sanz-Salvador, L. – Garcia-Perez, M. A. – Tarin, J. J., et al.: Endocrinology in pregnancy: Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture. *Eur J Endocrinol*, 2015, 172, s. R53–R65.
- 7 Rosa, J. – Šenk, F. – Palička, V.: *Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy 2015*, SMOS.
- 8 WHO Guideline: *Vitamin D supplementation in pregnant women*. Ženeva, World Health Organization, 2012.
- 9 Food and Agriculture Organization of the United Nations/World Health Organization: *Human vitamin and mineral requirements*. Report of a joint FAO/WHO expert consultation, Bangkok, Thajsko, 2001.
- 10 Masterjohn, C.: On the trail of the elusive X-factor: A sixty-two-year-old mystery finally solved. 2008. Dostupné z: <http://www.westonaprice.org/health-topics/abcs-of-nutrition/on-the-trail-of-the-elusive-x-factor-a-sixty-two-year-old-mystery-finally-solved/>, vyhledáno 2. 2. 2016.
- 11 Sliva, J.: Vitamin K u žen v postmenopauzálním období. *Klimakterická medicína*, 2012, 17, s. 5–8.
- 12 Walther, B. – Karl, P. J. – Booth, S. L. – Boyaval, P.: Menaquinones, bacteria, and the food supply: the relevance of dairy and fermented food products to vitamin K requirements. *Advances in Nutrition*, 2013, 4, s. 463–473.
- 13 Sato, T. – Schurgers, L. J. – Uenishi, K.: Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. *Nutrition Journal*, 2012, 11, s. 1–4.

Farmakologické ukončení těhotenství

MUDr. Michael Fanta, Ph.D. | MUDr. Karel Crha Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Fiala, Ch. – Cameron, S., et al.: *Early Medical Abortion—a practical guide to healthcare professionals*. Editions de Santé, 2012, dostupné z: http://www.spdc.pt/files/publicacoes/Early_medical_abortion.PDF, vyhledáno 11. 5. 2016.
- 2 Gibbon, L.: WHO puts abortifacients on its essential drug list. *BMJ*, 2005, 331, s. 68.
- 3 Jones, R. K. – Henshaw, S. K.: Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Dostupné z: <http://www.guttmacher.org/pubs/journals/3415402.html>, vyhledáno 11. 5. 2016.
- 4 ČSÚ: *Vývoj potratovosti v ČR 2003–2014*, 12/2015.
- 5 National Institute of Health and Welfare: *Induced abortions in the Nordic countries 2011*. Dostupné z: www.socialstyrelsen.se.
- 6 Vilmin, A., et al.: *Les interruptions volontaires de grossesse en 2011*. DREES Etudes et Résultats Juin 2013, 843.
- 7 Department of Health: *Abortion Statistics, England and Wales: 2011*. Dostupné z: <http://transparencity.dh.gov.uk/category/statistics/abortion>, vyhledáno 11. 5. 2016.
- 8 *Gesundheit – Schwangerschaftsabbrüche*. Statistisches Bundesamt, Fachserie 12, Reihe 3, 2012.
- 9 *Sanidad. Interrupción Voluntaria del Embarazo. Datos definitivos correspondientes al año*. Ministerio de Sanidad Servicios Sociales e Igualdad, 2012.
- 10 Office Fédéral de la Statistique. *Confédération suisse. Statistique des interruptions de grossesse*. Dostupné z: <http://www.bfs.admin.ch/bfs/portal/fr/index/themen/114/02/03/key/03.html>, vyhledáno 11. 5. 2016.
- 11 Sénat et Chambre des représentants de Belgique. *Rapport de la Commission nationale d'évaluation de la loi du 3 avril 1990 relative à l'interruption de grossesse*. 27. 8. 2012.
- 12 IGG: *Jaarrapportage 2012 van de Wet afbreking zwangerschap*.
- 13 Relatório dos registos das interrupções da grávidas ao abrigo de lei 16/2007 de 17 de abril. *Dados referentes ao período de janeiro a dezembro de 2012*.
- 14 Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute: *Interruzione volontaria di gravidanza. Ultimi aggiornamenti 19/12/13*. Dostupné z: <http://www.epicentro.iss.it/problemi/ivg/aggiornamenti.asp>, vyhledáno 11. 5. 2016.
- 15 Nordic International Data.
- 16 Doporučení k provádění prevence RhD aloimunitace u RhD negativních žen. *Čes Gynek*, 2013, 78, s. 132–133.
- 17 Frank, K. – Gerychová, R. – Janků, P., et al.: Farmakologické ukončení gravidity mifepristonem a misoprostolem – zhodnocení úspěšnosti, komplikací a spokojenosti pacientek. *Čes Gynek*, 2015, 80, s. 451–455.

Gynekologické operace a využití gelu Hyalobarrier

doc. MUDr. Eduard Kučera, CSc.

Gynekologicko-porodnická klinika 3. LF UK, Praha, Fakultní nemocnice Královské Vinohrady, Praha

- 1 Ahmad, G. – Mackie, F. L. – Iles, D. A., et al.: Fluid and pharmacological agents for adhesion prevention after gynaecological surgery. *Cochrane Database Syst Rev*, 2014, 9, 7, s. CD001298.
- 2 Alpay, Z. – Saed, G. M. – Diamond, M. P.: Postoperative adhesions: from formation to prevention. *Semin Reprod Med*, 2008, 26, s. 313–321.
- 3 Brokelman, W. J. – Holmdahl, L. – Bergström, M., et al.: Peritoneal fibrinolytic response to various aspects of laparoscopic surgery: a randomized trial. *J Surg Res*, 2009, 151, s. 89–93.
- 4 Brosens, I. – Gordon, A.: Bowel injuries during gynaecological laparoscopy: a multinational survey. *Gynaecol Endosc*, 2001, 10, s. 141–145.
- 5 Bryant, T.: Clinical lectures on intestinal obstruction. *Med Times Gaz*, 1872, 1, s. 363–365.
- 6 Džerega, G. S. – Campeau, J. D.: Peritoneal repair and post-surgical adhesion formation. *Hum Reprod Update*, 2001, 7, s. 547–555.
- 7 Ellis, H.: Medicolegal consequences of postoperative adhesions. *J Royal Soc Med*, 2001, 94, s. 331–332.
- 8 Guida, M. – Acunzo, G. – Di Spiezo Sardo, A., et al.: Effectiveness of auto-crosslinked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic surgery: a prospective, randomized, controlled study. *Hum Reprod*, 2004, 19, s. 1461–1464.
- 9 Holub, Z.: Klinické problémy a komplikace laparoskopického vstupu. *Čes Gynek*, 2000, 65, s. 464–470.
- 10 Cheong, Y. C. – Laird, S. M. – Shelton, J. B., et al.: Peritoneal healing and adhesion formation/ reformation. *Hum Reprod Update*, 2001, 7, s. 556–566.
- 11 Kumar, S. – Wong, P. F. – Leaper, D. J.: Intra-peritoneal prophylactic agents for preventing adhesions and adhesive intestinal obstruction after non-gynaecological abdominal surgery. *Cochrane Database Syst Rev*, 2009, CD005080.
- 12 Menzies, D. – Ellis, H.: Intestinal obstruction from adhesions—how big is the problem? *Ann R Coll Surg Engl*, 1992, 72, s. 60–63.
- 13 Monk, B. J. – Bermna, M. L. – Montz, F. J.: Adhesions after extensive gynecologic surgery: clinical significance, etiology and prevention. *Am J Obstet Gynecol*, 1994, 170, s. 1396–1403.
- 14 Nappi, C. – Di Spiezo Sardo, A. – Greco, E., et al.: Prevention of adhesions in gynaecological endoscopy. *Hum Reprod Update*, 2007, 13, s. 379–394.
- 15 Palaia, I. – Boni, T. – Angioli, R., et al.: Prevention of postoperative adhesions. *Minerva Ginecol*, 2009, 61, s. 57–66.
- 16 Parker, M. C. – Wilson, M. S. – Menzies, D., et al.: The SCAR-3 study: 5-year adhesion-related readmission risk following lower abdominal surgical procedures. *Colorectal Dis*, 2005, 7, s. 551–558.

- 17 Parker, M. C. – Ellis, H. – Moran, B. J., et al.: Postoperative adhesions: ten-year follow up of 12,584 patients undergoing lower abdominal surgery. *Dis Colon Rectum*, 2001, 44, s. 822–830.
- 18 Pellicano, M. – Guida, M. – Bramante, S., et al.: Reproductive outcome after autocrosslinked hyaluronic acid gel application in infertile patients who underwent laparoscopic myomectomy. *Fertil Steril*, 2005, 83, s. 498–500.
- 19 Practice Committee of the American Society for Reproductive Medicine: Pathogenesis, and control of peritoneal adhesions in gynecologic surgery. *Fertil Steril*, 2008, 90, s. S144–S149.
- 20 Rajab, T. K. – Wallwiener, M. – Talukdar, S. – Kraemer, B.: Adhesion-related complications are common, but rarely discussed in preoperative consent: a multicenter study. *World J Surg*, 2009, 33, s. 748–750.
- 21 Revaux, A. – Ducarme, G. – Luton, D.: Prevention of intrauterine adhesions after hysteroscopic surgery. *Gynecol Obstet Fertil*, 2008, 36, s. 311–317.
- 22 Thubert, T. – Dussaux, C. – Demoulin, G., et al.: Influence of auto-cross-linked hyaluronic acid gel on pregnancy rate and hysteroscopic outcomes following surgical removal of intrauterine adhesions. *Eur J Obstet Gynecol Reprod Biol*, 2015, 193, s. 65–69.
- 23 Trew, G.: Consensus in adhesion reduction management. *Obstet Gynaecol*, 2004, 6, s. 1–16.
- 24 Tulandi, T. – Al-Jaroudi, D.: Nonclosure of the peritoneum: a reappraisal. *Am J Obstet Gynecol*, 2003, 189, s. 609–612.
- 25 Wallwiener, C. W. – Kraemer, B. – Wallwiener, M., et al.: The extent of adhesion induction through electrocoagulation and suturing in an experimental rat study. *Fertil Steril*, 2010, 93, s. 1040–1044.
- 26 Wiseman, D. M.: Obtaining informed consent: patient awareness of adhesions. *Adhes News and Views*, 2003, 4, s. 10–12.

Transdermální aplikace estrogenní substituční terapie – spojení účinnosti a bezpečnosti

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Fait, T. – Vrablík, M. – Košťřová, M. – Trnková B.: Vliv různých aplikací forem estrogenní substituční terapie na hladiny C-reaktivního proteinu. *Čas Lék Čes*, 2006, 145, s. 571–574.
- 2 MacLennan, A. H. – Broadbent, J. L. – Lester, S. – Moore, V.: Oral oestrogen and combined oestrogen/progesterone therapy versus placebo for hot flushes. *Cochrane Database Syst Rev*, 2004, 4, CD 002978.
- 3 Fait, T. – Vrablík, M.: Coronary heart disease and hormone replacement therapy—from primary and secondary prevention to the window of opportunity. *Neuro Endocrinol Lett*, 2012, 33, dopl. 2, s. 17–21.
- 4 Egas, A. M. – Umland, E. M.: The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms. *Int J General Med*, 2010, 3, s. 147–151.
- 5 Scarabin, P. Y. – Oger, E. – Plu-Bureau, G.: Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. *Lancet*, 2003, 36, s. 428–432.
- 6 Vrablík, M. – Fait, T. – Kovar, J., et al.: Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. *Metabolism*, 2008, 57, s. 1088–1092.
- 7 Straczek, C. – Oger, E. – Yon de Jonage-Canonica, M. B., et al.: Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. *Circulation*, 2005, 112, s. 3495–3500.
- 8 Place, V. A. – Powers, M. – Darley, P. E., et al.: A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. *Am J Obstet Gynecol*, 1985, 152, s. 1092–1099.
- 9 Hillard, T. C. – Whitcroft, S. J. – Marsh, M. S., et al.: Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. *Osteoporosis*, 1994, 4, s. 341–348.
- 10 Ibarra de Palacios, P. – Schmidt, G. – Sergejew, T., et al.: Comparative study to evaluate skin irritation and adhesion of Estradot and Climara in healthy postmenopausal women. *Climacteric*, 2002, 5, s. 383–389.
- 11 Beral, V. – Banks, E. – Reeves, G.: Evidence from randomised trials on the long-term effects of HRT. *Lancet*, 2002, 360, s. 942–944.
- 12 Birkhauser, M. H. – Barlow, D. H. – Notelovitz, M., et al.: *Health plan for the adult woman*. Taylor and Francis, 2005, s. 248.
- 13 Straczek, C. – Oger, E. – Yon de Jonage-Canonica, M. B., et al.: Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. *Circulation*, 2005, 112, s. 3495–3500.
- 14 Renaus, C. – Dell'Aniello, S. – Garbe, E. – Suissa, S.: HRT use and the risk of stroke. *Mauritas*, 2008, 61, s. 305–309.
- 15 Godtsland, I. F.: Effects of postmenopausal HRT on lipid, protein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. *Fertility and Sterility*, 2001, 75, s. 898–915.
- 16 Perason, T. A. – Mensah, G. A. – Alexander, R. W., et al.: AHA/CDC scientific statement. Markers of inflammation and cardiovascular disease. *Circulation*, 2003, 107, s. 499–511.
- 17 Simon, J. A. – Boucahrd, C. – Waldbaum, A., et al.: Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal woman: a randomised controlled trial. *Obstet Gynecol*, 2007, 109, s. 588–596.
- 18 Archer, D. F. – Picker, J. H. – MacAlister, D. C. – Warren, M. P.: Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. *Menopause*, 2012, 19, s. 622–629.
- 19 Corbelli, J. – Shaikh, N. – Wessel, C. – Hess, R.: Low dose transdermal estradiol for vasomotor symptoms: a systematic review. *Menopause*, 2015, 22, s. 114–121.

Možnost hormonální léčby akné v ordinaci gynekologa

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha,

Katedra gynekologie a porodnictví 3. LF UK, Praha, Katedra gynekologie a porodnictví IPVZ, Praha

- 1 Kligman, A. M.: Postadolescent acne in women. *Cutis*, 1991, 48, s. 75–77.
- 2 Bataille, V. – Snieder, H. – MacGregor, A. J., et al.: The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. *J Invest Dermatol*, 2002, 119, s. 1317–1322.
- 3 Cordain, L. – Lindeberg, S. – Hurtado, M., et al.: Acne vulgaris: a disease of western civilization. *Arch Dermatol*, 2002, 138, s. 1584–1590.
- 4 Thiboutot, D. – Martin, P. – Volikos, L., et al.: Oxidative activity of the type 2 isozyme of 17β-Hydroxysteroid dehydrogenase (17β-HSD) predominates in human sebaceous glands. *J Invest Dermatol*, 1998, 111, s. 390–395.
- 5 Shaw, J.: Acne: Effects on hormones on pathogenesis and management. *Am J Clin Dermatol*, 2002, 3, s. 571–578.
- 6 Arowojolu, A. O. – Gallo, M. F. – Lopez, L. M., et al.: Combined oral contraceptive pills for treatment of acne. *Cochrane Database Syst Rev*, 2009, 3, CD004425.
- 7 O'Connell, K. – Westhoff, C.: Pharmacology of hormonal contraceptives and acne. *Cutis*, 2008, 81, s. 8–12.
- 8 Thiboutot, D. – Chen, W.: Update and future of hormonal therapy in acne. *Dermatology*, 2003, 206, s. 57–67.
- 9 Guida, M. – Bifulco, G. – Di Spiezo Sardo, G., et al.: Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. *International Journal of Women's Health*, 2010, 2, s. 279–290.
- 10 Thiboutot, D.: Acne: Hormonal concepts and therapy. *Clin Dermatol*, 2004, 22, s. 419–428.
- 11 Thiboutot, D.: Endocrinological evaluation and hormonal therapy for women with difficult acne. *J Eur Acad Dermatol Venereol*, 2001, 15, s. 57–61.
- 12 Sitruk-Ware, R.: New progestogens for contraceptive use. *Human Reproduction Update*, 2006, 12, s. 169–178.
- 13 Giorgi, E. – Shirley, L. – Grant, J., et al.: Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate. *Biochem J*, 1973, 132, s. 465–474.
- 14 Pham-Huu-Trung, M. – de Smitter, N. – Bogyo, A., et al.: Effects of cyproterone acetate on adrenal steroidogenesis in vitro. *Horm Res*, 1984, 20, s. 108–115.
- 15 Grunwald, K. – Rabe, T. – Schlereth, G., et al.: Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization. *Geburtshilfe Frauenheilkd*, 1994, 54, s. 634–645.
- 16 De Leo, V. – Di Sabatino, A. – Musacchio, M. C., et al.: Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. *Contraception*, 2010, 82, s. 276–280.
- 17 Teichmann, A.: Pharmacology of estradiol valerate/dienogest. *Climacteric*, 2003, dopl. 2, s. 17–23.
- 18 Foster, R. H. – Wilde, M. I.: Dienogest. *Drugs*, 1998, 56, s. 825–833.
- 19 George, R. – Clarke, S. – Thiboutot, D.: Hormonal therapy for acne. *Semin Cutan Med Surg*, 2008, 27, s. 188–196.
- 20 Feschl, F. H.: Pharmacology of estrogens and gestagens. In: Krause & Pachemegg. *Menopause andropause*. Gablitz, Krause und Pachemegg, 2001, s. 33–50.
- 21 Druckmann, R.: Profile of the progesterone derivative chlormadinone acetate—pharmacodynamic properties and therapeutic applications. *Contraception*, 2009, 79, s. 272–281.
- 22 Palombo-Kinne, E. – Schellsmidt, I. – Schumacher, U., et al.: Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. *Contraception*, 2009, 79, s. 282–289.
- 23 Di Carlo, C. – Gargano, V. – Sparice, S., et al.: Effects of an oral contraceptive mg ethinylestradiol/2 mg cyproterone acetate. *Contraception*, 2009, 79, s. 282–289.
- 24 Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study. *Gynecological Endocrinology*, 2013, 29, s. 1048–1050.
- 25 van Vloten, W. A. – van Haselen, C. W. – van Zuuren, E. J., et al.: The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. *Cutis*, 2002, 69, s. 2–15.
- 26 Koltun, W. – Lucky, A. W. – Thiboutot, D., et al.: Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. *Contraception*, 2008, 77, s. 249–256.
- 27 Maloney, J. M. – Dietze, P. – Watson, D., et al.: A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. *J Drugs Dermatol*, 2009, 8, s. 837–844.
- 28 Plewig, G. – Cunliffe, W. J. – Binder, N., et al.: Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. *Contraception*, 2009, 80, s. 25–33.
- 29 World Health Organization. Medical Eligibility for Contraceptive Use (4. vydání) 2010. Dostupné z: http://www.who.int/reproductive-health/publications/family_planning/9789241563888/en/index.html, vyhledáno 2. 5. 2016.
- 30 de Bastos, M. – Stegeman, B. H. – Rosendaal, F. R., et al.: Combined oral contraceptives: venous thrombosis. *Cochrane Database Syst Rev*. 2014, 3, CD010813, doi: 10.1002/14651858.CD010813.pub2.
- 31 Dinger, J. – Shapiro, S.: Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. *J Fam Plann Reprod Health Care*, 2012, 38, s. 2–6.
- 32 Bitzer, J. – Amy, J. – Seydoux, J., et al.: Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. *European Journal Of Contraception & Reproductive Health Care*, 2013, 18, s. 143–147.

Prevence karcinomu děložního hrdla na rozcestí: nové přístupy k použití HPV testu

MUDr. Mgr. Igor Piňos, CSc. Praha

- 1 **Isidean, S. I. – Franco, E. L.:** Embracing a new era in cervical cancer screening. 2013, dostupné z: [http://dx.doi.org/10.1016/S0140-6736\(13\)62028-0](http://dx.doi.org/10.1016/S0140-6736(13)62028-0), vyhledáno 25. 5. 2016.
- 2 Canadian Task Force on Preventive Healthcare, Recommendations on screening for cervical cancer. *CMAJ*, 2013, 180, s. 35–45.
- 3 **Ronco, G., et al.:** Efficacy of Human Papilloma Virus Testing on detection of invasive cervical cancers and cervical intraepithelial neoplasia. *Lancet Oncol*, 2010, 11, s. 249–257.
- 4 **Lynge, E. – Rygaard, C., et al.:** Cervical cancer screening at crossroads. *APMS*, 2014, 122, s. 667–673.
- 5 **Blatt, A., et al.:** Comparison of cervical cancer screening results. *Cancer Cytopathology*, 2015.